Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

The governor said his proposal to regulate pharmacy benefit managers, intermediaries that critics say drive up drug costs, ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

While supporters say it will help struggling rural pharmacies, opponents say it drives up costs for Iowans by tens of ...

Moreover, with 40–50% of generics imported, aggressive price cuts could make exports unviable for supplier and trigger a ...

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...

Biocon advanced 3.17% to Rs 328.75 after Biocon Biologics (BBL) secures multiple market access agreements in the United States for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab), ...

The 39 attorneys generals, which includes those representing United States territories and the District of Columbia ... Some of the top pharmacy benefit mangers are CVS Caremark, Express Scripts, ...

The Rite Aid closings could create pharmacy deserts in small communities like Eden and Silver Creek, which would be without a ...

While the proposal was nixed, Jordan wanted to use a spending bill to gut the Federal Trade Commission and its ability to ...